ABSTRACT
OBJECTIVE: To explore normalized and reasonable strategies of assisted reproductive technology (ART) for patients with end-stage renal disease (ESRD) under ethical supervision based on the experience with a case of ART for an ESRD male. METHODS: A male patient with ESRD successfully fathered a child through in vitro intracytoplasmic sperm injection (ICSI) in our center. We performed an epidemiological analysis, reviewed the relevant literature and explored the feasibility, ethical issues and strategies of ART for male patients with ESRD. RESULTS: ESRD affected the reproductive hormone levels, sperm quality and erectile function of the patient. Considering the contradictions between the reproductive right and the uncertainty of disease prognosis of the patient and the health of the offspring and his wife, we comprehensively evaluated the physical and mental conditions of the patient, obtained the informed consent, submitted the case to the Ethics Committee of Reproductive Medicine. CONCLUSIONS: With respect to ART for ESRD patients, importance should be attached to their rights of reproduction and choice of reproductive technology. In the process of ART, the physical conditions of the patient ought to be evaluated comprehensively and rigorously, and the related ethical principles followed strictly.
Subject(s)
Kidney Failure, Chronic , Patient Rights , Reproductive Techniques, Assisted/ethics , Humans , Informed Consent , Male , Sperm Injections, IntracytoplasmicABSTRACT
Uterine leiomyomas are common clinical gynecological tumors, which are a major health concern for many women. In the current study, we aimed to investigate the effect of paclitaxel (PTX) on uterine leiomyomas. A mouse model of uterine leiomyomas was established by estradiol benzoate, followed by treatment with increasing doses of PTX. PTX showed no dose-limiting toxicity that affected the survival of mice, and was able to restore the apoptosis level of uterus tissues of the model mice to normal levels. In this study, we discovered that PTX played a critical role in promoting apoptosis in the mouse model of uterine leiomyomas, which provides a new insight into the therapy of uterine leiomyomas.
Subject(s)
Apoptosis/drug effects , Leiomyoma/drug therapy , Paclitaxel/pharmacology , Uterus/drug effects , Animals , Disease Models, Animal , Female , Mice , Mice, Inbred C57BLABSTRACT
Polycystic ovary syndrome (PCOS) is a gynaecological endocrine disease. The objective of the present study was to investigate the role of GTPase immunity-associated protein (GIMAP) 7 in PCOS. A PCOS rat model was established using dehydroepiandrosterone injection. The data showed that GIMAP7 was mainly located in granulosa cells and was abundantly expressed in the ovarian granulosa cells of PCOS rats. GIMAP7 silencing decreased blood glucose levels, HOMA-IR scores, and number of cystic follicles. In addition, GIMAP7 silencing corrected erratic oestrous cycles, inhibited apoptosis and reduced c-caspase-3 protein expression in the ovarian tissues of PCOS rats. GIMAP7 silencing reduced malondialdehyde (MDA) but increased glutathione (GSH) and superoxide dismutase (SOD) levels in the serum and ovarian tissues of PCOS rats. The effects of GIMAP7 were further investigated in human ovarian granulosa KGN cells. GIMAP7 silencing increased the viability, promoted proliferation, and increased the percentage of S-phase KGN cells. The apoptosis rate was significantly decreased by GIMAP7 silencing. GIMAP7 also inhibited oxidative stress in KGN cells, resulting in decreased levels of reactive oxygen species (ROS) and MDA and increased levels of GSH and SOD. Notably, GIMAP7 inhibited the sonic hedgehog (SHH) signalling pathway, and GIMAP7 silencing increased the expression of the SHH signalling pathway downstream genes SHH, SMO, and Gli1. Inhibition of the SHH signalling pathway using cyclopamine reduced the effect of GIMAP7 silencing on KGN cells. This study proved that GIMAP7 promotes oxidative stress and apoptosis in ovarian granulosa cells in PCOS by inhibiting the SHH signalling pathway.
Subject(s)
Polycystic Ovary Syndrome , Humans , Female , Rats , Animals , Polycystic Ovary Syndrome/genetics , Polycystic Ovary Syndrome/metabolism , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Granulosa Cells/metabolism , Apoptosis , Oxidative Stress , GTP-Binding Proteins/metabolism , GTP-Binding Proteins/pharmacologyABSTRACT
Cervical cancer is the second most common cancer and the third leading cause of cancer-related death among females in less developed countries. Studies have shown that the single-nucleotide polymorphisms of interleukin 6 might be associated with cervical cancer risk. A total of 710 articles from EMBASE, EBSCO, Web of science, PubMed, Springer link, and Chinese National Knowledge Infrastructure databases were reviewed in our study. A meta-analysis on the associations between interleukin 6 rs1800795 polymorphism and cervical cancer risk was carried out by comparison using 5 genetic models. In this systematic review, 5 studies were analyzed. The pooled population included 2735 participants (1210 cases and 1525 controls). The overall odds ratio (G vs C alleles) using fixed-effects model was 0.85 (95% confidence interval 0.75-0.97), P = .02. Our results show that the C genotype of interleukin 6 rs1800795 is associated with higher cervical cancer risk. Our results indicate that interleukin 6 rs1800795 polymorphism might be associated with susceptibility to cervical cancer.
Subject(s)
Genetic Association Studies , Genetic Predisposition to Disease , Interleukin-6/genetics , Polymorphism, Single Nucleotide , Uterine Cervical Neoplasms/genetics , Alleles , Case-Control Studies , Female , Genotype , Humans , Linkage Disequilibrium , Odds RatioABSTRACT
BACKGROUND: Inflammation is involved in the pathogenesis of preeclampsia. Omentin is a newly discovered adipokine that possesses an anti-inflammatory function. The aim of this study was to determine the association of serum omentin-1 concentration with the presence and severity of preeclampsia. METHODS: Serum concentrations of omentin-1 were measured in 128 women with preeclampsia and 96 women with uncomplicated pregnancies using an enzyme-linked immunosorbent assay method. RESULTS: Patients with preeclampsia had significantly lower serum concentrations of omentin-1 compared to healthy controls. In addition, those patients with severe preeclampsia had significantly lower concentrations of serum omentin-1 compared to those with mild preeclampsia. Simple linear regression analysis showed that in patients with preeclampsia the serum concentrations of omentin-1 showed significant correlation with body mass index (P < 0.001), systolic blood pressure (P < 0.05) and homeostasis model assessment of insulin resistance (P < 0.001). CONCLUSION: Decreased concentrations of serum omentin-1 appear to be associated with the presence and severity of preeclampsia.